 Zacks Investment Research upgraded shares of BridgeBio Pharma NASDAQ:BBIO from a sell rating to a hold rating in a research note published on Tuesday morning, Zacks.com reports. According to Zacks, BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Companys product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline ... 